Covance — Merger or Acquisition (November 2014)
11 slides from Covance's merger presentation, Nov 4, 2014
Slide 1: Creating the world's leading health diagnostics company
Creating the world’s leading health diagnostics company Covance Joins With LabCorp 3 November 2014
Slide 2: Cautionary Statement Regarding Forward Looking Statements
Cautionary Statement Regarding Forward Looking Statements This communication contains “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These statements, as
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This document relates to a proposed transaction between Covance and LabCorp, which will become the subject of a registration statement and joint proxy statement/prospectus forming a part thereof to be filed with the SEC by LabCorp. This document is not a s
Slide 4: Our Strategic Journey
Our Strategic Journey Existing Core Business Near-Neighbor Opportunities Diversification Opportunities Disruptive Technology & Model Changes for ED, CLS, CDS Nutritional Chemistry & Food Safety Commercialization Informatics New markets & New Businesses
Slide 5: Translating Strategy Into Action
Translating Strategy Into Action Making Solutions Real through an innovative and industry leading partnership
Slide 6: Today's Disruptions, Tomorrow's Solutions
Today’s Disruptions, Tomorrow’s Solutions The world’s leading healthcare diagnostics company Covance Solutions Made Real
Slide 7: Who Is LabCorp?
Who Is LabCorp? Headquartered in Burlington, North Carolina Listed on New York Stock Exchange: LH Leader in commercializing new diagnostic technologies National network of primary clinical and specialty testing laboratories 34,000 employees worldwide More than 220,000 clients
Slide 8: New Organization Structure Will Maintain Covance Brand
New Organization Structure Will Maintain Covance Brand Combined company’s corporate headquarters in Burlington, North Carolina Led by Dave King, Chairman and CEO Covance Drug Development Division headquarters to remain in Princeton, New Jersey Led by Joe Herring Larger and more diversified global co
Slide 9: Transaction Milestones
Transaction Milestones Obtain shareholder and regulatory approvals Meet customary closing conditions Commence integration planning Joint integration planning team will ensure a smooth and orderly transition Steven Anderson, PhD, LabCorp Jared Freedberg, Covance Closing expected first quarter 2015, u
Slide 10: Our Commitment to You
Our Commitment to You A Smooth transition to the new company Continue to keep you informed with ongoing communications Additional information is available on Covance Insider CEO site visits in the coming weeks Meetings with your management to share department- and business unit-specific information
Slide 11: Questions?
Questions? ALabCorp ....... COVANCE > ‘SOLUTIONS MADE REAL ones 11] November, 3, 2014